As the fintech industry matures and separates the leaders from the laggards, two names are rising to the top. The money industry looks very different…
View More 2 Fintech Stocks to Buy With $3,000 and Hold Forever | The Motley FoolCategory: Investing
Stock Split Watch: Is This Magnificent Seven Stock (That’s Never Done a Split) Next? | The Motley Fool
This company aims to win in the AI race. All of the Magnificent Seven stocks — except one — have this in common: They’ve each…
View More Stock Split Watch: Is This Magnificent Seven Stock (That’s Never Done a Split) Next? | The Motley FoolQuantum Computing Stocks IonQ, Rigetti, and D-Wave Have Soared Up to 5,400% Over the Trailing Year — but History Offers a Dire Warning | The Motley Fool
History has a flawless track record of foreshadowing trouble for next-big-thing technologies and innovations — and quantum computing just made the list. Since the advent…
View More Quantum Computing Stocks IonQ, Rigetti, and D-Wave Have Soared Up to 5,400% Over the Trailing Year — but History Offers a Dire Warning | The Motley FoolWhy PayPal Stock Was Surging This Week | The Motley Fool
Investors liked what they heard about two new company initiatives. Investors have been extremely willing to pay for PayPal (PYPL -0.49%) stock over the past…
View More Why PayPal Stock Was Surging This Week | The Motley FoolIs Sezzle Stock a Bargain After Crashing by 40%? | The Motley Fool
Sezzle has crushed the market year to date, but a 50% decline has some investors on edge. Sezzle (SEZL 0.27%) had a hot start to…
View More Is Sezzle Stock a Bargain After Crashing by 40%? | The Motley FoolUSA Rare Earth Skyrocketed Today — Is the Stock a Buy? | The Motley Fool
USA Rare Earth shareholders just got news that could potentially power an extended rally. USA Rare Earth (USAR 14.99%) posted huge gains in Thursday’s trading…
View More USA Rare Earth Skyrocketed Today — Is the Stock a Buy? | The Motley FoolWhy Cidara Therapeutics Stock Crushed It Today | The Motley Fool
The company earned an important fast-track review designation for a pipeline medication. The leading pipeline drug being developed by Cidara Therapeutics (CDTX 12.53%) got a…
View More Why Cidara Therapeutics Stock Crushed It Today | The Motley FoolStocks Retreat as Shutdown Continues: Stock Market Today
Stocks trended lower throughout Thursday’s session, as worries about the ongoing government shutdown began to creep higher. Market participants also got a first look at…
View More Stocks Retreat as Shutdown Continues: Stock Market TodayDelta (DAL) Q3 2025 Earnings Call Transcript | The Motley Fool
Image source: The Motley Fool. DATE Thursday, Oct. 9, 2025, at 10 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Ed Bastian President — Glen…
View More Delta (DAL) Q3 2025 Earnings Call Transcript | The Motley FoolWhy The Metals Company Stock Is Skyrocketing This Week | The Motley Fool
Yet again, this would-be mining stock demonstrates that the rumor mill can power sharp increases in share prices. With October in full swing, many are…
View More Why The Metals Company Stock Is Skyrocketing This Week | The Motley Fool